Tech Company Financing Transactions

NKT Therapeutics Funding Round

SV Health Investors and MedImmune Ventures participated in a $8 million Series A capital raise for NKT Therapeutics. The round was announced on 3/16/2009.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

58 Deborah Sampson St.
Sharon, MA 02067
USA

Phone

(781) 534-4177

Website

www.nktrx.com

Email Address

[email protected]

Overview

NKT Therapeutics, Inc. is a biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. NKT cells are a rare but central component of the human immune system which plays a pivotal role in human health and disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Robert Mashal

        

Chief Scientific Officer

Robert Schaub

        

VP - Finance

Ron Goldstein

        

Browse more venture capital transactions:

Prev: 3/16/2009: Acclaris venture capital transaction
Next: 3/16/2009: AnySource Media venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to record funding rounds that are announced publicly. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary